Header Logo

Connection

Ian Sanne to Male

This is a "connection" page, showing publications Ian Sanne has written about Male.
Connection Strength

2,543
  1. Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting. PLoS One. 2022; 17(9):e0270545.
    View in: PubMed
    Score: 0,090
  2. Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
    View in: PubMed
    Score: 0,063
  3. Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
    View in: PubMed
    Score: 0,060
  4. Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis. 2014 Nov; 18(11):1340-6.
    View in: PubMed
    Score: 0,052
  5. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
    View in: PubMed
    Score: 0,052
  6. CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc. 2014; 17:19139.
    View in: PubMed
    Score: 0,052
  7. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
    View in: PubMed
    Score: 0,048
  8. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
    View in: PubMed
    Score: 0,048
  9. Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapy. Nutr J. 2013 Aug 06; 12:111.
    View in: PubMed
    Score: 0,048
  10. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
    View in: PubMed
    Score: 0,047
  11. Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012 Sep 10; 26(14):1823-8.
    View in: PubMed
    Score: 0,045
  12. Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
    View in: PubMed
    Score: 0,044
  13. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
    View in: PubMed
    Score: 0,044
  14. Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar; 113(3):362-72.
    View in: PubMed
    Score: 0,043
  15. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
    View in: PubMed
    Score: 0,041
  16. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,040
  17. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010 Sep 14; 5(9):e12731.
    View in: PubMed
    Score: 0,039
  18. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,039
  19. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,038
  20. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010 Apr; 15(4):405-13.
    View in: PubMed
    Score: 0,038
  21. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,035
  22. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 Mar 15; 191(6):825-9.
    View in: PubMed
    Score: 0,027
  23. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Med. 2022 06; 19(6):e1004024.
    View in: PubMed
    Score: 0,022
  24. Persistent Symptoms among Frontline Health Workers Post-Acute COVID-19 Infection. Int J Environ Res Public Health. 2022 May 13; 19(10).
    View in: PubMed
    Score: 0,022
  25. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 06; 29(6):474-486.
    View in: PubMed
    Score: 0,022
  26. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022 03 19; 399(10330):1141-1153.
    View in: PubMed
    Score: 0,022
  27. Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442.
    View in: PubMed
    Score: 0,022
  28. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021; 16(6):e0252317.
    View in: PubMed
    Score: 0,021
  29. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
    View in: PubMed
    Score: 0,021
  30. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. Lancet Glob Health. 2021 05; 9(5):e628-e638.
    View in: PubMed
    Score: 0,021
  31. Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. J Acquir Immune Defic Syndr. 2020 11 01; 85(3):280-291.
    View in: PubMed
    Score: 0,020
  32. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,018
  33. Treatment outcomes among HIV-positive orphaned and non-orphaned children on antiretroviral therapy in Johannesburg, South Africa. S Afr Med J. 2019 Aug 28; 109(9):679-685.
    View in: PubMed
    Score: 0,018
  34. HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study. Lancet HIV. 2019 07; 6(7):e438-e446.
    View in: PubMed
    Score: 0,018
  35. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis. 2019 05 02; 68(10):1739-1746.
    View in: PubMed
    Score: 0,018
  36. "Even if you're HIV-positive there's life after if you take your medication": experiences of people on long-term ART in South Africa: a short report. AIDS Care. 2019 08; 31(8):973-978.
    View in: PubMed
    Score: 0,018
  37. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. BMC Pulm Med. 2019 Jan 07; 19(1):4.
    View in: PubMed
    Score: 0,017
  38. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
    View in: PubMed
    Score: 0,017
  39. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
    View in: PubMed
    Score: 0,017
  40. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS One. 2018; 13(10):e0204020.
    View in: PubMed
    Score: 0,017
  41. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018 06 18; 67(1):34-41.
    View in: PubMed
    Score: 0,017
  42. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health. 2018 06; 23(6):650-660.
    View in: PubMed
    Score: 0,017
  43. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
    View in: PubMed
    Score: 0,017
  44. Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
    View in: PubMed
    Score: 0,016
  45. Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review. Clin Infect Dis. 2017 10 01; 65(7):1226-1228.
    View in: PubMed
    Score: 0,016
  46. Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
    View in: PubMed
    Score: 0,016
  47. Client uptake of safer conception strategies: implementation outcomes from the Sakh'umndeni Safer Conception Clinic in South Africa. J Int AIDS Soc. 2017 03 08; 20(Suppl 1):21291.
    View in: PubMed
    Score: 0,015
  48. Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
    View in: PubMed
    Score: 0,015
  49. Evaluation of the Tsima community mobilization intervention to improve engagement in HIV testing and care in South Africa: study protocol for a cluster randomized trial. Implement Sci. 2017 Jan 17; 12(1):9.
    View in: PubMed
    Score: 0,015
  50. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
    View in: PubMed
    Score: 0,015
  51. Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
    View in: PubMed
    Score: 0,015
  52. Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa. PLoS One. 2016; 11(12):e0168118.
    View in: PubMed
    Score: 0,015
  53. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,015
  54. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
    View in: PubMed
    Score: 0,015
  55. Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis. 2016 11 08; 16(1):661.
    View in: PubMed
    Score: 0,015
  56. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 01; 17(1):39-49.
    View in: PubMed
    Score: 0,015
  57. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
    View in: PubMed
    Score: 0,015
  58. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,015
  59. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016 May; 13(5):e1002015.
    View in: PubMed
    Score: 0,015
  60. The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. PLoS One. 2016; 11(2):e0148546.
    View in: PubMed
    Score: 0,014
  61. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016 May 01; 62(9):1081-8.
    View in: PubMed
    Score: 0,014
  62. Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
    View in: PubMed
    Score: 0,014
  63. Vitamin D, D-dimer, Interferon ?, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. EBioMedicine. 2016 Feb; 4:115-23.
    View in: PubMed
    Score: 0,014
  64. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol. 2016 08; 22(4):472-8.
    View in: PubMed
    Score: 0,014
  65. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
    View in: PubMed
    Score: 0,014
  66. Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):323-8.
    View in: PubMed
    Score: 0,014
  67. "I don't know if this is right … but this is what I'm offering": healthcare provider knowledge, practice, and attitudes towards safer conception for HIV-affected couples in the context of Southern African guidelines. AIDS Care. 2016; 28(3):390-6.
    View in: PubMed
    Score: 0,014
  68. Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study. Int J STD AIDS. 2016 10; 27(11):984-92.
    View in: PubMed
    Score: 0,014
  69. Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
    View in: PubMed
    Score: 0,014
  70. The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
    View in: PubMed
    Score: 0,014
  71. The impact of Xpert(®) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015 Apr; 19(4):392-8.
    View in: PubMed
    Score: 0,013
  72. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
    View in: PubMed
    Score: 0,013
  73. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
    View in: PubMed
    Score: 0,013
  74. High uptake of systematic HIV counseling and testing and TB symptom screening at a primary care clinic in South Africa. PLoS One. 2014; 9(9):e105428.
    View in: PubMed
    Score: 0,013
  75. Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. 2014 Dec; 19(12):1411-9.
    View in: PubMed
    Score: 0,013
  76. Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS. 2014 Jul; 28 Suppl 3:S277-85.
    View in: PubMed
    Score: 0,013
  77. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,013
  78. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8.
    View in: PubMed
    Score: 0,013
  79. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
    View in: PubMed
    Score: 0,012
  80. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
    View in: PubMed
    Score: 0,012
  81. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17:18651.
    View in: PubMed
    Score: 0,012
  82. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
    View in: PubMed
    Score: 0,012
  83. Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS. 2014 Jan 28; 28(3):417-24.
    View in: PubMed
    Score: 0,012
  84. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9.
    View in: PubMed
    Score: 0,012
  85. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
    View in: PubMed
    Score: 0,012
  86. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,012
  87. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0,012
  88. Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay. BMJ Case Rep. 2013 Aug 28; 2013.
    View in: PubMed
    Score: 0,012
  89. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,012
  90. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,012
  91. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis. 2013 Nov; 32(11):1409-15.
    View in: PubMed
    Score: 0,012
  92. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
    View in: PubMed
    Score: 0,012
  93. HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):839-44.
    View in: PubMed
    Score: 0,012
  94. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
    View in: PubMed
    Score: 0,012
  95. The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
    View in: PubMed
    Score: 0,012
  96. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e39-46.
    View in: PubMed
    Score: 0,012
  97. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
    View in: PubMed
    Score: 0,012
  98. Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS One. 2013; 8(1):e49140.
    View in: PubMed
    Score: 0,012
  99. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health. 2013 Jan; 18(1):109-16.
    View in: PubMed
    Score: 0,011
  100. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,011
  101. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S96-104.
    View in: PubMed
    Score: 0,011
  102. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
    View in: PubMed
    Score: 0,011
  103. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,011
  104. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis. 2012 Sep; 55(6):868-76.
    View in: PubMed
    Score: 0,011
  105. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,011
  106. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,011
  107. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
    View in: PubMed
    Score: 0,011
  108. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
    View in: PubMed
    Score: 0,011
  109. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
    View in: PubMed
    Score: 0,011
  110. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,011
  111. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
    View in: PubMed
    Score: 0,010
  112. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,010
  113. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,010
  114. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011 Oct; 17(5):438-47.
    View in: PubMed
    Score: 0,010
  115. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011 Jul; 8(7):e1001055.
    View in: PubMed
    Score: 0,010
  116. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493-505.
    View in: PubMed
    Score: 0,010
  117. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,010
  118. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010 Dec 07; 13:49.
    View in: PubMed
    Score: 0,010
  119. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,010
  120. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One. 2010 Jul 01; 5(7):e11416.
    View in: PubMed
    Score: 0,010
  121. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:43-7.
    View in: PubMed
    Score: 0,010
  122. Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ. 2010 Sep 01; 88(9):675-80.
    View in: PubMed
    Score: 0,010
  123. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,010
  124. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52.
    View in: PubMed
    Score: 0,010
  125. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,009
  126. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4(5):e5575.
    View in: PubMed
    Score: 0,009
  127. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug; 7(4):200-7.
    View in: PubMed
    Score: 0,008
  128. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008 Jul; 22 Suppl 1:S131-9.
    View in: PubMed
    Score: 0,008
  129. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008 Jul; 98(7):541-4.
    View in: PubMed
    Score: 0,008
  130. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007 Jul; 97(7):524-9.
    View in: PubMed
    Score: 0,008
  131. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15; 43(6):783-6.
    View in: PubMed
    Score: 0,007
  132. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006 May; 28(5):745-54.
    View in: PubMed
    Score: 0,007
  133. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006 Apr 15; 42(8):1179-86.
    View in: PubMed
    Score: 0,007
  134. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
    View in: PubMed
    Score: 0,006
  135. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
    View in: PubMed
    Score: 0,006
  136. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
    View in: PubMed
    Score: 0,006
  137. Periappendiceal hydatidosis: an unusual cause of right iliac fossa pain. Br J Surg. 1994 Sep; 81(9):1371-2.
    View in: PubMed
    Score: 0,003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.